SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...

With studies showing potential for SGLT2 inhibitors in heart failure, a study of HCP online conversations reveals cardiologists are still cautious. AstraZeneca had already been quick to consider ...

These benefits were more pronounced with long-term use, as cumulative incidence rates were not as apparent after 1 year of therapy. Additionally, SGLT-2 inhibitors showed a trend toward reducing ...

SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.

Use of SGLT2 inhibitors was associated with a lower risk for rhabdomyolysis than DPP-4 inhibitors among statin users. Sodium-glucose cotransporter-2 (SGLT2) inhibitor use is associated with a ...

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

If you continue to have this issue please contact [email protected]. Starting SGLT2 inhibitors led to a lower risk of eGFR decline or incident kidney failure. SGLT2 inhibitors were also ...

Opens in a new tab or window Comparative effectiveness study followed adults with type 2 diabetes who initiated SGLT-2 inhibitors from 2014 to 2020. Real-world outcomes largely point to comparable ...

A recent study from the University of Hong Kong suggests that a newer type of diabetes drug, called sodium-glucose cotransporter 2 inhibitors (SGLT2i), may help protect the kidneys and lungs in people ...

sodium-glucose transporter 2 (SGLT2) inhibitors — these reduce the amount of glucose reabsorbed by the kidneys, meaning that it is excreted in the urine. A meta-analysis, published in the Journal of ...